Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival
ConclusionDespite novel hormonal drugs, docetaxel still plays an important role in the treatment of mCRPC. Patients with partial-PSA-response at rechallenge or a treatment-free interval > 3 m benefit most from docetaxel re-exposure.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Docetaxel | Hormones | Prostate Cancer | Study | Taxotere | Urology & Nephrology